Continuous ambulatory peritoneal dialysis in familial Mediterranean fever amyloidosis patients with end-stage renal failure

Basit Öğe Kaydı
dc.authoridAltiparmak, Mehmet Riza/0000-0002-3579-1100
dc.authorwosidAltiparmak, Mehmet Riza/AAC-2508-2021
dc.authorwosidAtaman, Muveddet Rezzan/AAA-9042-2020
dc.contributor.authorAltiparmak, MR
dc.contributor.authorPamuk, ÖN
dc.contributor.authorAtaman, R
dc.contributor.authorSerdengeçti, K
dc.date.accessioned2024-06-12T11:01:47Z
dc.date.available2024-06-12T11:01:47Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground/Aims: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterised by recurrent fever attacks and polyserositis which may lead to the development of AA amyloidosis and end-stage renal disease ( ESRD). In this study, we aimed to evaluate the efficacy of continuous ambulatory peritoneal dialysis (CAPD) in FMF-amyloidosis patients with ESRD. Methods: Forty age- and sex-matched patients undergoing CAPD at our centre between 1996 and 2002 were included in the study. Of these, 10 had FMF-amyloidosis, 10 had diabetes mellitus (DM), 10 had chronic glomerulonephritis (CGN) and 10 had chronic interstitial nephritis (CIN). Efficiency of CAPD, development of complications, presence of other diseases and survival were compared. Results: With the onset of ESRD, the frequency of FMF peritonitis attacks decreased, with less attacks occurring during CAPD in FMF-amyloidosis patients (p < 0.05). There was no significant difference between the FMF-amyloidosis group and other groups in terms of efficiency of CAPD, peritoneal function, complications and survival. DM patients had a shorter survival period compared with CGN and CIN patients (p < 0.05), but there was no survival difference between FMF-amyloidosis patients and other groups (p > 0.05). Conclusions: We conclude that CAPD is an effective and safe renal replacement therapy for FMF-amyloidosis patients with ESRD. Copyright (C) 2004 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000081553
dc.identifier.endpageC123en_US
dc.identifier.issn1660-2110
dc.identifier.issue4en_US
dc.identifier.pmid15627789en_US
dc.identifier.scopus2-s2.0-11244346710en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpageC119en_US
dc.identifier.urihttps://doi.org/10.1159/000081553
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21017
dc.identifier.volume98en_US
dc.identifier.wosWOS:000226046400005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofNephron Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFamilial Mediterranean Feveren_US
dc.subjectSecondary Amyloidosis (AA Type)en_US
dc.subjectContinuous Ambulatory Peritoneal Dialysisen_US
dc.subjectColchicineen_US
dc.titleContinuous ambulatory peritoneal dialysis in familial Mediterranean fever amyloidosis patients with end-stage renal failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu